AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	129.59	171.46	122.4
Cash & Cash Equivalents	129.59	171.46	122.4
Cash Growth	-	40.08%	-
Other Current Assets	-	2.39	17.07
Total Current Assets	-	173.85	139.47
Property, Plant & Equipment	-	0.62	-
Goodwill and Intangibles	-	30.1	30.33
Other Long-Term Assets	-	1.8	1.46
Total Long-Term Assets	-	32.51	31.79
Total Assets	-	206.36	171.26
Accounts Payable	-	8.05	8.28
Current Debt	-	0.27	0.18
Other Current Liabilities	-	0.8	2.42
Total Current Liabilities	-	9.13	10.89
Long-Term Debt	-	1.27	1.44
Other Long-Term Liabilities	-	7.88	7.5
Total Long-Term Liabilities	-	9.15	8.94
Total Liabilities	-	18.28	19.82
Total Debt	1.33	1.55	1.62
Debt Growth	-	-4.63%	-
Retained Earnings	-	-119.18	-72.83
Shareholders' Equity	146.93	188.08	151.44
Net Cash (Debt)	128.26	169.91	120.78
Net Cash (Debt) Growth	-	40.68%	-
Working Capital	-	164.72	128.59

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).